ProvIDHe, an early access Phase 3b study of ivosidenib in patients with pretreated locally advanced or metastatic cholangiocarcinoma.

On 31 January 2024, NICE approved the targeted therapy ivosidenib (TIBSOVO®) for those with cholangiocarcinoma who have an IDH1 mutation, and who have already undergone one other treatment.  To see the full guidance from NICE, click here 

Therefore, the ProvIDHe study has now closed to recruitment in the UK.  

For further information on this study see:

Back to previous page